Recent Updates
Recently added Catalysts
PHGE Positive Sentiment

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

Wednesday, March 27, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BiomX Inc. has announced a conference call and webcast scheduled for April 3rd, 2024, at 8:00 a.m. ET, to report its fourth quarter and full year 2023 financial results. The call will also provide a business update outlining the company's advancements in phage therapies. BiomX focuses on targeting and destroying pathogenic bacteria, further promoting its role as a clinical-stage innovator in chronic disease treatment. The event will be accessible via phone and the company’s website for investors.
Price reaction · baseline $63.783 (2024-03-26 close) · hit after-hours · clean, no other PHGE news in the window
day 0 close
+6.1%
day 1 · peak
+34%
day 3
+14.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • BiomX is advancing novel phage therapies targeting specific bacteria.
  • The upcoming conference call will provide important financial updates.
  • Increased visibility on their financial performance and business strategies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+190%
120-day peak, hindsight
Typical move
13.4%
average across 4 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
BX002-A
Phase 1 · Healthy Volunteers

Full Press Release Details

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, April 3rd, 2024, at 8:00 a.m. ET, to report fourth quarter and full year 2023 financial results and a provide business update.
To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
BiomX is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com.
Corporate Project Manager

Frequently Asked Questions

When will BiomX report its financial results?

BiomX will report its fourth quarter and full year 2023 financial results on April 3rd, 2024.

How can I participate in the BiomX conference call?

To join the conference call, dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International).

Where can I find the webcast of the conference call?

The live and archived webcast will be available in the Investors section at www.biomx.com.

What does BiomX specialize in?

BiomX specializes in developing natural and engineered phage therapies targeting pathogenic bacteria.

How does BiomX customize its phage compositions?

BiomX customizes phage compositions by discovering and validating proprietary bacterial targets.

ShareAdd on Google
Tags: PHGE Viatris Investor Conferences Healthcare BiomX clinical-stage financial results phage therapies
Last updated: Mar 27, 2024

Biotech snapshot

Cash runway
$1M liquidity · $0M/mo burn
~1 mo
High dilution risk
Lead asset
BX002-APhase 1
Healthy Volunteers →

Catalyst track record

+190%
best trade around PHGE's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PHGE.

See every catalyst's timing & PoA →